HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Boro-Scopol

HCID 3000322
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
51-34-3
Standard SMILES
CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
InChIKey
STECJAGHUSJQJN-FWXGHANASA-N
Molecular formula
C17H21NO4
Average molar mass
303.35 g/mol
Monoisotopic mass
303.14705815

Overview

Scopolamine is a tropane alkaloid that is the (S)-tropic acid ester of 6beta,7beta-epoxy-1alphaH,5alphaH-tropan-3alpha-ol. It has a role as a metabolite, an antidepressant, a muscarinic antagonist, a mydriatic agent, an antiemetic, an antispasmodic drug, an anaesthesia adjuvant and an adjuvant. It is an epoxide, a propanoate ester, a tropane alkaloid and a tertiary amino compound. It is functionally related to a (S)-tropic acid. It is a conjugate base of a scopolamine(1+).

Names & identifiers

Preferred name
Boro-Scopol
IUPAC
[(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
English name
Scopolamine
Molecular formula
C17H21NO4
Molecular weight
303.35

Names & synonyms

ScopaceBoro-ScopolRefChem:570028scopolamineHyoscine(-)-Hyoscine51-34-3Scopine tropateTransderm-Scop(-)-ScopolamineScopine (-)-tropateAtrochin
Show more names
Scopolamine powderSEEScopodermScopPHLPPC01851PHLPP1PLEKHE1
AtroquinHyosoll-Scopolamine6,7-Epoxytropine tropateEpoxytropine tropateIsopto HyoscineScopolamine hydrobromideScopamin

Database identifiers

CAS
51-34-3
PubChem CID
3000322
DTXSID
DTXSID6023573
ChEMBL
CHEMBL1906925、CHEMBL3084722、CHEMBL4065982
ChEBI
CHEBI:16794
UNII
DL48G20X8X
Nikkaji
J47.151H

Properties

Computed structural propertiesFilling in

XLogP
0.9
Topological polar surface area
62.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
5
Rotatable bonds
5
Heavy atoms
22
Formal charge
0
Complexity
418

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Solubility1.0X10+5 mg/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Adjuvants, Anesthesia; Mydriatics; Muscarinic Antagonists; Parasympatholytics
Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Dissociation Constants7.75
Collision Cross Section · 3 items

171.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID0032029]

171.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

170.5 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

Physicochemical properties

Melting point
59 · 59 ºC

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

ridadr
UN 1544PSN2 6.1 / PGII
hs_code
29399990
Toxicity
A belladonna plant alkaloid that exerts its pharmacodynamic effects by blocking muscarinic acetylcholine receptor sites. The s.c. LD50 of scopolamine hydrobromide in mice is 3.8 g/kg. Scopolamine crosses the blood brain barrier, and its antimuscarinic effects include, in therapeutic doses, drowsiness, euphoria, amnesia, fatigue, loss of REM sleep and, at higher doses, restlessness or even delirium. Scopolamine can be used to treat motion sickness and parkinsonian tremor. The effects of scopolamine may be greater in the CNS than atropine, and it may be a better antidote for organophosphate intoxication.
risk_code
26/27/28
Signal word
Danger
Symbol(GHS)
GHS05,GHS06
hazard_code
T+
safety_code
25-45
Hazard statements
H300+H310+H330-H317-H318
REACH Registrations
Active
Precautionary statements
P260-P262-P280-P302+P352+P310-P304+P340+P310-P305+P351+P338
Hazardous Substances Data
51-34-3(Hazardous Substances Data)

Chemistry & industry

Pharmacology

ATC CodeA04AD01
Protein BindingScopolamine may reversibly bind plasma proteins in humans. In rats, scopolamine exhibits relatively low plasma protein binding of 30 ± 10%.
Pharmacodynamics · 1 item

Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remains detectable in urine over a period of 108 hours. Scopolamine is contraindicated in angle-closure glaucoma and should be used with caution in patients with open-angle glaucoma due to scopolamine's ability to increase intraocular pressure. Also, scopolamine exhibits several neuropsychiatric effects: exacerbated psychosis, seizures, seizure-like, and other psychiatric reactions, and cognitive impairment; scopolamine may impair the ability of patients to operate machinery or motor vehicles, play underwater sports, or perform any other potentially hazardous activity. Women with severe preeclampsia should avoid scopolamine. Patients with gastrointestinal or urinary disorders should be monitored frequently for impairments, and scopolamine should be discontinued if these develop. Scopolamine can cause blurred vision if applied directly to the eye, and the transdermal patch should be removed before an MRI procedure to avoid skin burns. Due to its gastrointestinal effects, scopolamine can interfere with gastric secretion testing and should be discontinued at least 10 days before performing the test. Finally, scopolamine may induce dependence and resulting withdrawal symptoms, such as nausea, dizziness, vomiting, gastrointestinal disturbances, sweating, headaches, bradycardia, hypotension, and various neuropsychiatric manifestations following treatment discontinuation; severe symptoms may require medical attention.

Mechanism of Action · 1 item

[Acetylcholine] (ACh) is a neurotransmitter that can signal through ligand-gated cation channels (nicotinic receptors) and G-protein-coupled muscarinic receptors (mAChRs). ACh signalling via mAChRs located in the central nervous system (CNS) and periphery can regulate smooth muscle contraction, glandular secretions, heart rate, and various neurological phenomena such as learning and memory. mAChRs can be divided into five subtypes, M1-M5, expressed at various levels throughout the brain. Also, M2 receptors are found in the heart and M3 receptors in smooth muscles, mediating effects apart from the direct modulation of the parasympathetic nervous system. While M1, M3, and M5 mAChRs primarily couple to G<sub>q</sub> proteins to activate phospholipase C, M2 and M4 mainly couple to G<sub>i/o</sub> proteins to inhibit adenylyl cyclase and modulate cellular ion flow. This system, in part, helps to control physiological responses such as nausea and vomiting. Scopolamine acts as a non-selective competitive inhibitor of M1-M5 mAChRs, albeit with weaker M5 inhibition; as such, scopolamine is an anticholinergic with various dose-dependent therapeutic and adverse effects. The exact mechanism(s) of action of scopolamine remains poorly understood. Recent evidence suggests that M1 (and possibly M2) mAChR antagonism at interneurons acts through inhibition of downstream neurotransmitter release and subsequent pyramidal neuron activation to mediate neurological responses associated with stress and depression. Similar antagonism of M4 and M5 receptors is associated with potential therapeutic benefits in neurological conditions such as schizophrenia and substance abuse disorders. The significance of these observations to scopolamine's current therapeutic indications of preventing nausea and vomiting is unclear but is linked to its anticholinergic effect and ability to alter signalling through the CNS associated with vomiting.

Related reactions

1 records
New reaction record
HRID 1670355 reaction equation
HRID 1670355As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
alpha
20 · D20 -28° (c = 2.7)
Boiling point
444.28 °C · 444.28°C (rough estimate)
Density
1.31 · 1.31
refractive index
1.5022 · 1.5022 (estimate)
Flash point
232.2 ℃ · 232.2℃
storage temp.
-20 °C · -20°C
solubility
Soluble in water, freely soluble in ethanol (96 per cent).
pka
7.55 · 7.55-7.81(at 25℃)
form
55 °C · 55°C liquid
color
White to off-white
Water Solubility
95 g/L · 95g/L(15 ºC)
LogP
0.98 · 0.980
FDA UNII
48 G20X8X · DL48G20X8X
ATC code
4 AD01,A04AD51,N05CM05,S01FA02 · A04AD01,A04AD51,N05CM05,S01FA02
NIST Chemistry Reference
Scopolamine(51-34-3)
EPA Substance Registry System
1 · Benzeneacetic acid, .alpha.-(hydroxymethyl)-, (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester, (.alpha.S)- (51-34-3)
Symbol(GHS)
5 · GHS05,GHS06
Signal word
Danger
Hazard statements
300 · H300+H310+H330-H317-H318
Precautionary statements
260 · P260-P262-P280-P302+P352+P310-P304+P340+P310-P305+P351+P338
Hazard Codes
T+
Risk Statements
26 · 26/27/28
Safety Statements
25 · 25-45
RIDADR
1544 PSN2 · UN 1544PSN2 6.1 / PGII
HS Code
29399990 · 29399990
Hazardous Substances Data
51 · 51-34-3(Hazardous Substances Data)
Toxicity
50 of · A belladonna plant alkaloid that exerts its pharmacodynamic effects by blocking muscarinic acetylcholine receptor sites. The s.c. LD50 of scopolamine hydrobromide in mice is 3.8 g/kg. Scopolamine crosses the blood brain barrier, and its antimuscarinic effects include, in therapeutic doses, drowsiness, euphoria, amnesia, fatigue, loss of REM sleep and, at higher doses, restlessness or even delirium. Scopolamine can be used to treat motion sickness and parkinsonian tremor. The effects of scopolamine may be greater in the CNS than atropine, and it may be a better antidote for organophosphate intoxication.
REACH Registrations
Active
Biological Half-Life · 1 item

The half-life of scopolamine differs depending on the route. Intravenous, oral, and intramuscular administration have similar half-lives of 68.7 ± 1.0, 63.7 ± 1.3, and 69.1 ±8/0 min, respectively. The half-life is greater with subcutaneous administration at 213 min. Following removal of the transdermal patch system, scopolamine plasma concentrations decrease in a log-linear fashion with a half-life of 9.5 hours.

Metabolism/Metabolites · 1 item

Little is known about the metabolism of scopolamine in humans, although many metabolites have been detected in animal studies. In general, scopolamine is primarily metabolized in the liver, and the primary metabolites are various glucuronide and sulphide conjugates. Although the enzymes responsible for scopolamine metabolism are unknown, _in vitro_ studies have demonstrated oxidative demethylation linked to CYP3A subfamily activity, and scopolamine pharmacokinetics were significantly altered by coadministration with grapefruit juice, suggesting that CYP3A4 is responsible for at least some of the oxidative demethylation.

MeSH Pharmacological Classification · 5 items

Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage.

Drugs used to prevent NAUSEA or VOMITING.

Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics.

Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Absorption, Distribution and Excretion · 4 items

The pharmacokinetics of scopolamine differ substantially between different dosage routes. Oral administration of 0.5 mg scopolamine in healthy volunteers produced a Cmax of 0.54 ± 0.1 ng/mL, a tmax of 23.5 ± 8.2 min, and an AUC of 50.8 ± 1.76 ng\*min/mL; the absolute bioavailability is low at 13 ± 1%, presumably because of first-pass metabolism. By comparison, IV infusion of 0.5 mg scopolamine over 15 minutes resulted in a Cmax of 5.00 ± 0.43 ng/mL, a tmax of 5.0 min, and an AUC of 369.4 ± 2.2 ng\*min/mL. Other dose forms have also been tested. Subcutaneous administration of 0.4 mg scopolamine resulted in a Cmax of 3.27 ng/mL, a tmax of 14.6 min, and an AUC of 158.2 ng\*min/mL. Intramuscular administration of 0.5 scopolamine resulted in a Cmax of 0.96 ± 0.17 ng/mL, a tmax of 18.5 ± 4.7 min, and an AUC of 81.3 ± 11.2 ng\*min/mL. Absorption following intranasal administration was found to be rapid, whereby 0.4 mg of scopolamine resulted in a Cmax of 1.68 ± 0.23 ng/mL, a tmax of 2.2 ± 3 min, and an AUC of 167 ± 20 ng\*min/mL; intranasal scopolamine also had a higher bioavailability than that of oral scopolamine at 83 ± 10%. Due to dose-dependent adverse effects, the transdermal patch was developed to obtain therapeutic plasma concentrations over a longer period of time. Following patch application, scopolamine becomes detectable within four hours and reaches a peak concentration (tmax) within 24 hours. The average plasma concentration is 87 pg/mL, and the total levels of free and conjugated scopolamine reach 354 pg/mL.

Following oral administration, approximately 2.6% of unchanged scopolamine is recovered in urine. Compared to this, using the transdermal patch system, less than 10% of the total dose, both as unchanged scopolamine and metabolites, is recovered in urine over 108 hours. Less than 5% of the total dose is recovered unchanged.

The volume of distribution of scopolamine is not well characterized. IV infusion of 0.5 mg scopolamine over 15 minutes resulted in a volume of distribution of 141.3 ± 1.6 L.

IV infusion of 0.5 mg scopolamine resulted in a clearance of 81.2 ± 1.55 L/h, while subcutaneous administration resulted in a lower clearance of 0.14-0.17 L/h.

Uses & manufacturing

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Applications · 5 items

DescriptionScopolamine is a type of alkaloid that exists in a variety of Solanaceae plants such as Scopolia japonica, Datura metel L., and so on. It is the main active ingredient in these plants.Apart from scopolamine, several other chemical ingredients also exist in Scopolia japonica, including hyoscyamine, anisodamine, anisodine, and so on. Hyoscyamine is an inhibitor of parasympathetic nerve, with the analgesic and antispasmodic functions, especially for sciatica, sometimes for the treatment of epilepsy, seasickness, etc., and its pharmacological effects are similar to atropine. However, its clinical application is less because of its toxicity. The clinical applications of anisodamine are treating infectious toxic shock, vascular disorders, various neuralgia, smooth muscle spasms, vertigo, fundus disorders and sudden deafness, and other diseases. It has definite curative effect and is widely used in clinical in China. Its synthetic product is called “654-2,” which now still is an effective drug to treat infectious shock and other vascular diseases. While anisodine is used to treat vascular headache, retinal vasospasm, ischemic optic neuritis, cerebrovascular disease, acute paralysis, central dysfunction caused by carbon monoxide poisoning, tremor, paralysis, bronchial asthma, motion sickness, organophosphorus pesticide poisoning, and so on .

HistoryScopolamine is the main active ingredient of Scopolia japonica, Datura metel L., and other Solanaceae plants. As early as 1892, the chemist E.Schmidt first isolated it from the Scopolia japonica, so named it as scopolamine. Due to its obvious deficiencies in solubility and usage, the researchers modified its structure as scopolamine butylbromide, which was synthesized and used scopolamine and bromo-n-butane with heating refluxing method. Preparation method of scopolamine butylbromide is simple, and it’s easy to be synthesized. There are about 170 domestic enterprises producing its raw materials currently.European Pharmacopoeia (9th ed.), United States Pharmacopeia (36), and the Japanese Pharmacopoeia (16th ed.) contained bromine scopolamine; British Pharmacopoeia (2015) contained the raw materials and preparations of scopolamine butylbromide, including tablets and injections. Pharmacopoeia of the People’s Republic of China (2015) contained its raw materials, injection, and capsules.

UsesScopolamine is used for practically the same indications as atropine, but it should be noted that it has a sedative effect on motor activity, and it is recommended for the treatment of Parkinsonian symptoms.

Usescholinergic (ophthalmic).

General DescriptionScopolamine (hyoscine) is found in variousmembers of the Solanaceae (e.g., H. niger, Duboisia myoporoides,Scopolia spp., and Datura metel). Scopolamineusually is isolated from the mother liquor remaining from theisolation of hyoscyamine.Hyoscine is the older name for this alkaloid, althoughscopolamine is the accepted name in the United States.Scopolamine is the levo component of the racemic mixturethat is known as atroscine. The alkaloid is racemized readilyin the presence of dilute alkali.The alkaloid occurs in the form of a levorotatory, viscousliquid that is only slightly soluble in water but very solublein alcohol, chloroform, or ether. It forms crystalline saltswith most acids, with the hydrobromide being the most stableand the most popularly accepted. An aqueous solution ofthe hydrobromide containing 10% mannitol is said to be lessprone to decomposition than unprotected solutions.

Additional notes

DefinitionChEBI: A tropane alkaloid that is the (S)-tropic acid ester of 6beta,7beta-epoxy-1alphaH,5alphaH-tropan-3alpha-ol.